Press Release   -

Automated Breast Ultrasound System (ABUS) Market to Reach Valuation of USD 1807.3 Million by 2028 - Rising breast cancer incidences and prevalence is Driving the Market

In terms of revenue, the global Automated Breast Ultrasound System (ABUS) market is expected to reach USD 1807.3 Million by 2028, growing at a Compound Annual Growth Rate (CAGR) of 15.9% from 2022 to 2028. Rising breast cancer incidences and prevalence, increasing radiology market and rising awareness with breast cancer toward the breast density is fueling the demand for the Automated Breast Ultrasound System (ABUS) market.

Key Findings:

• The automated breast ultrasound system is anticipated to hold a significant share for Automated Breast Ultrasound System (ABUS) market at a substantial Compound Annual Growth Rate (CAGR). Automated Breast Ultrasound System (ABUS) is safe, quick, and non-invasive, also women who have dense breasts are at a large risk of developing cancer, and Automated Breast Ultrasound System is efficient in detecting mammographically hidden cancer in women, while it has a lower sensitivity. Radiologists can see better what can’t be drawn on the mammogram, with an ultrasound, and a mammogram it helps with detection at any age, particularly in the case of dense breasts.
• Hospitals sub-segment held a market significant share in 2021. Automated Breast Ultrasound System (ABUS) decreases operator dependence and enables speedy scanning time. It also enhances the accuracy, reliability, reproducibility, and sensitivity of each person’s breast ultrasound diagnosis.
• North America is the largest regional segment. This is due to the increasing prevalence of cancer and the existence of key players in nations in the region. Additionally, women with no history of cancer were even recommended under the U.S. guidelines of screening of receiving mammograms when they turn age 40 or 50. They were recommended to carry on once every 1 or 2 years, and this is continued till or around age 75.

Some of key players in Automated Breast Ultrasound System (ABUS) market include - GE Healthcare (US), Siemens AG (Germany), Koninklijke Philips N.V. (Netherlands), Hitachi Ltd. (Japan), and SonoCine Inc. (US)..

A rapidly increasing number of breast cancer cases globally is a key factor in increasing the growth of the Automated Breast Ultrasound System (ABUS) Market globally. Other major factors resulting in increased incidences of breast cancer are obesity, hormone replacement therapy, age-related complications and decreased childbearing, which is turn is fueling the need for more accurate diagnosis and need for screening due to risks of further complications.

Constant advancements in technology in breast cancer systems for detection is a key driving factor for the growth of the Automated Breast Ultrasound System (ABUS) Market globally. Different sectors are working on the growth of a number of technologies to enhance cancer screening in women with dense breast cancer, therefore rising the breast cancer detection effectiveness. Also, advancements in Automated Breast Ultrasound System (ABUS) are expected to overcome disadvantages in conventional

Asia Pacific is expected to emerge as the largest market growth in 2021. This is attributed to the rising treatment and awareness of this breast cancer among women in nations in the region. Increasing awareness, particularly in some developing nations in the region, is ensuing more women approaching centers and camps for diagnosis and screening. Several organizations in nations conduct breast cancer awareness programs in the region, as well as events to raise funds for Research and Development (R&D) of more innovative treatment processes.